Center-Authored Papers

Filters: Author is Walter, R B  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Buckley SA, Othus M, Estey EH, Walter RB.  2015.  The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy.. Blood cancer journal. 5:e276.
Buckley SA, Appelbaum FR, Walter RB.  2012.  Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.. Bone marrow transplantation. Abstract
C
Chen X, Newell LF, Xie H, Walter RB, Pagel JM, Sandhu VK, Becker PS, Hendrie PC, Abkowitz JL, Appelbaum FR et al..  2015.  Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.. Leukemia.
G
Godwin CD, Gale RP, Walter RB.  2017.  Gemtuzumab ozogamicin in acute myeloid leukemia.. Leukemia. Abstract
H
Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL et al..  2017.  Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.. Leukemia. Abstract
Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB.  2017.  Measurable residual disease testing in acute myeloid leukaemia.. Leukemia. Abstract
K
Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J et al..  2017.  Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.. Leukemia. Abstract
L
Laszlo GS, Gudgeon CJ, Harrington KH, Walter RB.  2015.  T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.. Blood cancer journal. 5:e340. Abstract
O
Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, Erba HP, Walter RB.  2016.  Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.. Leukemia.
V
Vainstein V, Buckley SA, Shukron O, Estey EH, Abkowitz JL, Wood BL, Walter RB.  2013.  Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia.. Leukemia.
W
Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee J-W, Sun Z, Tallman MS, Patel J, Gönen M et al..  2015.  Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.. Leukemia.
Walter RB, Estey EH.  2014.  Management of older or unfit patients with acute myeloid leukemia.. Leukemia. Abstract
Walter RB, Laszlo GS, Lionberger JM, Pollard JA, Harrington KH, Gudgeon CJ, Othus M, Rafii S, Meshinchi S, Appelbaum FR et al..  2014.  Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.. Leukemia. Abstract
Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR et al..  2015.  Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.. Leukemia. 29(1):137-44. Abstract
Walter RB, Buckley SA, White E.  2012.  Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. Abstract
Z
Zhou Y, Wood BL, Walter RB, Becker PS, Percival M-E, Bar M, Shaw C, Gardner K, Hendrie P, Abkowitz J et al..  2017.  Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed? Leukemia. Abstract
Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.  2016.  Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.. Leukemia. Abstract